Esperion Therapeutics (ESPR) Depreciation & Amortization (CF) (2012 - 2026)
Esperion Therapeutics (ESPR) posted Depreciation & Amortization (CF) of $27000.0 for Q1 2026, up 28.57% on a QoQ basis from $21000.0 in Q4 2025, and up 3.85% year-over-year from $26000.0 in Q1 2025.
Esperion Therapeutics (ESPR) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $27000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 3.85% year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101000.0 (down 19.84% YoY) and the FY2025 annual result came in at $100000.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) was $27000.0 for Q1 2026 at Esperion Therapeutics, up from $21000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $153000.0 in Q1 2022 and bottomed at $10000.0 in Q2 2024.
- A 5-year average of $57937.5 and a median of $34500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 80.39% — and 2025, when it surged 170.0%.
- Esperion Therapeutics' Depreciation & Amortization (CF) stood at $92000.0 in 2022, then sank by 54.35% to $42000.0 in 2023, then soared by 52.38% to $64000.0 in 2024, then tumbled by 67.19% to $21000.0 in 2025, then climbed by 28.57% to $27000.0 in 2026.
- Business Quant data shows ESPR's Depreciation & Amortization (CF) at $27000.0 in Q1 2026, $21000.0 in Q4 2025, and $26000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 21,000.00 |
| Dec 31, 2025 | 21,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | 26,000.00 |
| Sep 30, 2024 | 26,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Sep 30, 2023 | 26,000.00 |
| Sep 30, 2023 | 26,000.00 |